December 27, 2006 – Targacept received a $20 million milestone from AstraZeneca for an Alzheimers drug; OXiGENE said CA4P, its anti-angiogenesis cancer drug, met Phase II trial endpoints; Dutch biotech Crucell will cross-license vaccine technology with Merck; Bristol-Myers Squibb out-licensed the Japanese rights for its type 2 diabetes drug candidate; BioVeris bought a non-exclusive license to a meningitis/sepsis vaccine; and Adams Respiratory requested FDA approval of a solid, extended-release cough medication, its first prescription product. The Centient Biotech 200™ rose 11 points to 3930, a gain of .29%. More details...
